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Purpose: We aimed to provide an overview of current un-
derstanding on the potential use of irreversible electropora-
tion (IRE) in the field of hepatobiliary surgery with a focus 
on current results in hepatic and pancreatic cancers, its 
limitations, and its current directions.
Methods: Through a review of the literature we have gath-
ered the key articles and trials that are shaping our under-
standing of the current status of IRE and its prospective 
uses, and organized them in an easily understandable for-
mat showcasing the most up to date results.
Results: IRE appears to be comparable in effectiveness and 
postoperative pain to the more established thermal ablation 
methods, while having the benefit of avoiding their detri-
mental thermal effects. In liver cancer, IRE was shown to 
be efficacious with low levels of local recurrences and only 
minimal complications. In pancreatic cancer it proved to 
have significant survival benefits but more significant (al-
though rare) complications compared to the ones seen when 
IRE is used in liver cancer. Current evidence suggests a 
promising future for IRE, but clinical randomized control 
trials, and further developments of treatment protocols are 
required to come to more stable conclusions on the effective-
ness and safety of IRE.
Conclusions: IRE is proving to be an adequate method 
for the treatment of tumors of the pancreas and liver in 
cases where traditional methods are unavailable. It has 
been proven particularly efficacious in patients with 
masses in close proximity to vital structures such as ves-
sels, as well as major biliary and hepatic structures where 
thermal methods of ablation would cause significant com-
plications.
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The past 20 years have witnessed much re-
search on the various ablative modalities for the 
treatment of focal liver and pancreatic tumors. 
This has led to tumor ablation being a recog-
nized adjunct in the arsenal of hepatobiliary can-
cer treatment options for patients where surgical 
resection is not an option [1,2]. More specifically, 
ablation is now broadly indicated for patients with 
inoperable malignancies that do not show spread 
of the tumor to other parts of the body [3].
Through the use of local ablative modalities, 
various types of energy can be implemented to 
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pass through a tumor in a controlled manner, so 
as to induce tissue destruction [4,5]. These ablative 
methods are grouped into thermal and non-ther-
mal modalities which are separated based on the 
mechanism by which they induce cell death [4]. 
The most common thermal modality of ablation 
is Radiofrequency Ablation (RFA), while the most 
common non-thermal modality of ablation is IRE. 
Among others, RFA and IRE are reported as the 
most emerging local ablative methods used in 
hepatobiliary surgery [6].
Ablative techniques are used to cause a focal 
destruction of a tumor which in turn has the ther-
apeutic potential to slow down disease progres-
sion and improve survival [4,7]. Within the field of 
hepatobiliary surgery, the aims of ablation include 
improving quality of life by cytoreduction leading 
to better symptom palliation, downstaging for sub-
sequent resection, and prolonging survival [1,8,9].
Among hepatobiliary surgeons, IRE is of spe-
cial interest as its non-thermal properties of ab-
lation allow it to be implemented in anatomical 
regions which were previously considered inac-
cessible. More specifically, IRE is a modality of 
ablation which can be used in the treatment of 
tumors located near bile ducts and blood vessels 
which are ineligible for surgical resection or ther-
mal ablation [1].
The IRE procedure itself is performed under 
general anesthesia, and can be done transcuta-
neously, laparoscopically, or by open procedure 
[1,3,10]. The full operation lasts between 2 to 4 
hrs, with active ablation times lasting 2 to 3 min 
[3,10-12]. Under optimal circumstances, IRE al-
lows patients to be discharged as early as the fol-
lowing day [3].
Methods
The review of the literature focused on keyword 
searches of electronic databases, such as MEDLINE, 
Embase, Cochrane Library, and Google Scholar for arti-
cles dated past the year 2000. Our search terms includ-
ed ‘irreversible electroporation’, ‘pancreatic cancer’, 
‘liver cancer’, ‘ablation’, ‘tumor’, ‘resection’, ‘indica-
tions’, in various configurations. We selected relevant 
case series, retrospective studies, case-control studies, 
and narrative and systematic reviews. Through further 
review of the selected articles and hand-picked refer-
ences, we formulated this narrative review.
Results
Irreversible electroporation
IRE was first introduced as a method of tumor 
ablation by Roubinky’s group in 2005 [10,13-15]. 
Until then, IRE was only known as an uninten-
tional complication of reversible electroporation 
which was used in conjunction with cytotoxic 
drugs to treat cancer through electrochemothera-
py [10,13]. This led to the first reported in vivo use 
of IRE on animals by Edd et al. in 2006 [14], and 
the first reported use of IRE on humans by Pech 
et al. in 2011 [11]. In 2007, Bertacchini et al. were 
the first to report an IRE system approved for clin-
ical use [12].
Since then, multiple studies have demon-
strated the efficacy of IRE in inducing cell death 
in a multitude of organs [10]. Animal studies have 
reported successful use of IRE for the ablation of 
cancers in the liver [13,14,16-18], pancreas [19,20], 
breast [21], prostate [22], kidney [23], lung [24], 
brain [25-30], and sarcomas [31,32]. In humans, 
IRE has been successfully used for the ablation of 
cancers in the liver [33,34], lung [35,36], pancreas 
[37-40], kidney [23,41,42], and prostate [43].
IRE works by manipulating the normal elec-
tric potential gradient which is present across all 
cellular membranes. Through creation of elec-
tric energy pulses, the transmembrane potential 
is affected leading to the disruption of the lipid 
bilayer. This then leads to the creation of perma-
nent pores in the cell membrane which inhibit the 
cell’s ability to maintain homeostasis and thus in-
duces cell apoptosis [1,6,10,13-15,17,44-46].
The unique non-thermal properties of IRE 
lead to its ability to spare structures with high 
quantities of collagen and elastic fibers [10]. By 
keeping the collagen scaffold intact, vital struc-
tures such as the pancreatic ducts, bile ducts, por-
tal triad, blood vessels, and nerves can be spared 
of destruction. Furthermore, these structures are 
then able to regenerate so as to bring back full 
function of the cells which were ablated [1,10,13-
17,19,20,22,23,33,47-57]. An example of this prop-
erty is nerve cells ablated through IRE showing a 
regenerative potential due to the retained intact 
architecture of the endoneurium and perineurium 
[1,10,52,55].
IRE is also not affected by heat sink, the cool-
ing effect which is seen in thermal ablative meth-
ods mediated by adjacent blood flow in the area 
of ablation [48,51]. This is of crucial importance 
to hepatobiliary surgeons as IRE permits the 
ablation of tumors close to vascular structures 
[17,22,49,50], which is not an option with thermal 
ablative techniques due to heat sink.
Finally, IRE is a method which can be per-
formed through minimally invasive procedures, 
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largely in part to the feasibility of periprocedural 
imaging [6,10]. Lee et al. [16,17] have demonstrat-
ed real-time ultrasound (US) image-guided percu-
taneous IRE in which a spherical hypoechoic area 
of ablation is created during and immediately af-
ter the procedure. The finding is reported to last 
24 hrs before it turns from a hypoechoic area to a 
hyperechoic area [16,17]. In addition to real-time 
imaging, studies have also demonstrated the abil-
ity of computed tomography (CT) and magnetic 
resonance imaging (MRI) to demarcate measur-
able areas of ablation within the first 24 hrs after 
ablation [3,6,10,16,25,58-63].
Taking into account the non-thermal proper-
ties of IRE including the lack of heat sink, it’s well 
demarcated histological borders, and its feasibil-
ity with the use of real-time US imaging, IRE en-
joys the benefit of being able to be implemented 
in the ablation of much larger lesions in addition 
to causing much less complications compared to 
other ablative methods [10,13-15,17,44,50,64].
IRE compared to thermal ablative methods
As a non-thermal ablative method, IRE differs 
from other ablative methods in a number of ways. 
When compared to thermal ablative methods, 
such as RFA, IRE has a number of advantages that 
stem from the difference in the mechanism of in-
duced cell death. Namely, IRE induces cell apop-
tosis compared to RFA which causes coagulative 
cell necrosis [10]. Apoptosis by IRE leads to cell 
removal by phagocytosis, meaning that the abil-
ity for innate cellular regeneration by surviving 
adjacent cells is retained and thus function may 
return in the ablated region [17,50]. Coagulative 
necrosis by thermal ablation does not posses this 
property as protein denaturation in conjunction 
with the subsequent scarring and fibrosis of the 
ablated region leads to tissue losing its poten-
tial for regeneration [17,50]. In addition to the 
retained regenerative potential, IRE also benefits 
from well demarcated borders of ablation which 
are not seen in thermal ablative methods where 
heat dissipates to adjacent tissue [17,50].
Some potential drawbacks of IRE which are 
not seen in other ablative methods stem from 
the powerful electric field which is required to be 
applied to the tumor [1]. In particular, these po-
tential complications include cardiac arrhythmias 
and severe muscle contractions [1,66]. Measures 
do exist to reduce, or eliminate, the occurrence of 
these complications. Cardiac arrhythmias may be 
prevented through the careful use of electrocar-
diograph (ECG) synchronizers which allow for the 
administration of electrical field pulses in rhythm 
with the heart’s refractory period [10-12,65-67]. 
The potential for severe muscle contractions may 
be reduced through the use of neuromuscular 
blocking agents, under general anesthesia, to pre-
vent any muscle contractions [10,68]. This can be 
done during the interval of 90 to 100 IRE electri-
cal pulses typically required for the full adminis-
tration of ablation, which is synchronized to 90 to 
100 heartbeats [10-12].
Table 1. Summary of major IRE trials for liver cancer
Authors No. of patients No. of 
lesions
Tumor type  
(No. of cases)
Primary 
efficacy
%
Complications Follow up time
Cannon et al. [34] 44 48 HCC (14)
CRLM (20)
Other (10)
97 5 12 months
Cheung et al. [72] 11 18 HCC (11) 67 4 18 months
Kingham et al. [33] 28 65 HCC (11)
CRLM (21)
Other (5)
96 4 6 months
Narayan et al. [70] 21 29 HCC (21) - 3 -
Nissen et al. [75] 1 1 HCC (1) 100 0 -
Nissen et al. [74] 1 1 CRLM (1) 100 0 -
Scheffer et al. [76] 10 10 CRLM (10) 90 0 4 weeks
Silk et al. [73] 9 19 CRLM (8)
Other (1)
- 3 9 months
Sugimoto et al. [77] 5 6 HCC (6) 83 0 9 months
Thomson et al. [67] 13 45 CRLM (6)
Other (7)
67 2 -
CRLM:colorectal liver metastasis, HCC:hepatocellular carcinoma
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Postoperative pain is a variable that has also 
been examined. Thus far, the research shows no 
significant difference in postoperative pain be-
tween patients that have undergone IRE and RFA 
ablation [69,70].
IRE in the field of hepatobiliary surgery
Liver cancer
IRE was found effective for ablating liver ma-
lignancies in preclinical studies. In a study of 35 
New Zealand White Rabbits implanted with large 
VX2 liver tumor, those treated with multiple IRE 
cycles consistently showed complete cell death 
and complete tumor ablation [71].
In clinical studies IRE was also deemed to be 
efficacious (Table 1). In a retrospective study of 28 
patients treated with IRE, only 4 out of the 65 tu-
mors treated showed local recurrence at 6 months 
[33] and no mortality was associated with the pro-
cedure itself. Another study looking at 44 patients 
having undergone IRE for liver tumors and metas-
tases near vital structures also showed a 97% initial 
procedure success rate without any mortality asso-
ciated to the procedure itself [34]. This study also 
showed a 94% recurrence free survival at 6 months 
from the procedure, but that number dropped to 
59.5% at the 12-month mark [34]. One other study 
of 11 patients treated for 18 lesions showed 6 local 
recurrences within an 18-month follow up [72].
Minimal complications were seen from IRE 
procedures. Amongst the studies looking at pa-
tients having undergone IRE, only few compli-
cations were reported, the majority of which 
were considered to be minor and unrelated to 
the IRE itself. The relevant complications related 
to IRE included pneumothorax, pleural effusion, 
hemothorax, transient arrhythmias, uncontrolled 
muscle contractions, transient increase in systolic 
blood pressure, pain, liver capsule puncture with-
out subcapsular hemorrhage, neurogenic bladder, 
and different-sites pain [34,67,69,70,72-77].
Pancreatic cancer
Initially trialed in swine, IRE was found ef-
ficacious in producing irreversible cell death in 
healthy pancreatic tissue in two independent 
studies [19,20]. It was also observed that if the 
spacing between the probe was more than 15 mm 
with the lower voltage used, the electroporation 
was reversible [19]. A study in 40 mice implanted 
with human pancreatic ductal adenocarcinoma, 
24 of which were treated with IRE, once the tu-
mor grew to 2-5 mm in diameter a 25% complete 
ablation rate was noticed with an 18% recurrence 
rate, increasing the median survival from 42 days 
in the untreated group to 88 days in the IRE group 
[57].
Fewer clinical studies have been performed 
on the use of IRE for pancreatic cancer (Table 
2). Martin et al. released the first trial of IRE on 
pancreatic cancer showing only one single 90-
day mortality out of the 27 patients that under-
went the intervention [37]. Also two studies by 
Narayanan et al. [39] with 14 patients and Marti-
net et al. [40] with 54 patients showed no mortal-
ity. A multicenter study by Philips et al. showed 
a demonstrable learning curve of at least 5 cases 
before becoming proficient with the use of IRE 
[78] suggesting that training has the capacity to 
decrease those rates.
Complications encountered in pancreatic IRE 
are incomplete ablation, duodenal leaks, pancre-
atitis, nausea/vomiting, infection, severe pain, 
DVT with PE, bile leak, biliary strictures, pan-
creatic abscess, and pancreaticoduodenal fistula 
[37,39,40,78-80]. A contraindication to the proce-
dure would be prior presence of a metallic bile 
stent, as it could lead to perforation of the duode-
num and colon, and potentially death by hemor-
rhage [80].
Mortality data from varying sources follow-
ing IRE procedures, in addition to standard che-
motherapy, have shown survival ranging from me-
dians of 7.5 months to 24.9 months [37-40,78,79], 
Table 2. Summary of major IRE trials for pancreatic cancer
Authors No. of patients Primary efficacy (%) Complications
(No. of patients)
Follow up time
Bagla et al. [38] 1 100 0 6 months
Martin et al. [37] 27 96 4 90 days
Martin et al. [40] 54 94 32 12 months
Martin et al. [79] 200 - 74 20 months
Narayanan et al. [39] 14 100 4 14 months
Paiella et al. [80] 10 100 2 15 months
Philips et al. [78] 59 - - 18 months
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with the largest study of 200 patients showing a 
median survival of 24.9 months [79].
Current status and future perspectives of IRE
IRE is a relatively new ablative method that 
has not yet seen wide implementation and re-
quires further research to examine its efficacy 
and safety. In the UK, IRE is only partly offered by 
the National Health Service (NHS) through few 
clinical trials, or can be performed privately at a 
price of roughly 15,000 pounds [3]. With regard 
to the current status of scientific knowledge on 
IRE, there is still insufficient evidence to safely 
come to conclusions about its long term benefits 
[6]. In addition, higher level research studies such 
as randomized controlled trials comparing IRE to 
other ablative methods are still not available in 
the literature [6]. A number of topics that are yet 
to be fully investigated and answered in IRE in-
clude its potential for adverse thermal effects, its 
necessity for an immune reaction following abla-
tion, the potential use of concurrent electrochem-
otherapy, novel methods of monitoring ablation, 
and determining the ultimate treatment protocol.
Currently, IRE is described as a non-thermal 
ablative process, however tissue damage due to 
thermal energy has been reported in the literature 
[1,82]. More specifically, heat damage following 
IRE has been described immediately adjacent to 
the IRE electrodes [82], as well as around metallic 
stents which could be heated up due to the con-
ductive nature of the metal [6,84]. As the possibil-
ity of thermal injury and occlusion of vital struc-
tures during IRE has not yet been ruled out, it 
has been recommended that electrodes should be 
placed at least 2 mm away from central bile ducts, 
pancreatic ducts, and intestinal tissue [1,73].
Another field of interest for its potentials in 
the use of IRE ablation is the molecular events 
that take place following the procedure. One such 
example is the involvement of the immune sys-
tem after performing IRE [6]. While there is ev-
idence to support enhanced immune antitumor 
stimulation after IRE [84,85], Al-Sakere et al. 
demonstrated a lack of local infiltration of tumor 
cells in the ablated tissue [31]. This is a point of 
interest as further evidence to support a lack of 
immune system involvement in the process of ab-
lation could lead to the successful implementa-
tion of IRE in immunosuppressed patients [6]. An 
additional point of interest in the molecular level 
is the concurrent use of electrochemotherapy to 
kill any remnant tumor cells [1,86]. Successful use 
of concurrent electrochemotherapy has the poten-
tial for a reduced rate of recurrence, especially for 
larger tumors which currently show the greatest 
likelihood of local recurrence [33,34,67,72,73].
Further knowledge on the monitoring meth-
ods and their capabilities in IRE is also required. 
In addition to monitoring IRE ablation by US, 
CT, and MRI in the first 24 hrs, particular inter-
est exists in the results of real-time monitoring 
modalities, and their subsequent correlations to 
long-term treatment outcomes [1,16,63,71,87]. Po-
tential interest for IRE monitoring also exists in 
the measurement of changes in the electric con-
ductivity of the ablated tissue. This is a technique 
reported as another potential mode of measuring 
the ablation effect [1,87-90].
One more frontier in our current knowledge 
of IRE with great potential to enhance our future 
implementation of this technique is the treat-
ment protocol. The outcome of ablation by IRE 
depends on a number of IRE parameters (number, 
shape, and length of electrical pulses, interval be-
tween pulses, field amplitude, polarity) [10,91], 
and cell parameters (type, morphology, age, size) 
[10,15,92-97]. Determining the ideal IRE parame-
ters for the treatment protocol by mathematical 
models has proven difficult, as tumor cell popula-
tions in vivo are never homogeneous and always 
in different stages of development [10,91]. This 
adds a considerable level of complexity in finding 
ideal IRE treatment protocols [10,91].
Last but not least, reports in the literature 
identify accurate electrode placement as the most 
challenging IRE parameter to optimize, even with 
an open surgical approach [10,98]. Updated elec-
trodes, electrode stabilizers, and imaging guiding 
systems are currently being researched and their 
results are awaited [10].
Conclusion
In conclusion, IRE appears to be a promising 
technique in the field of hepatobiliary surgery. It 
emerges as an adequate method for the treatment 
of tumors of the pancreas and liver in cases where 
traditional methods are unavailable or deemed to 
have a high risk for complications. IRE has been 
proven particularly efficacious in patients with 
masses in close proximity to vital structures such 
as vessels, as well as major biliary and hepat-
ic structures. It is of major importance that IRE 
avoids thermal effects where traditional methods 
of ablation would cause significant complications 
related their thermal effects. As rigorous studies 
addressing much of the unknown variables left to 
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be polished, we strongly believe that IRE is set to 
become the next breakthrough in late-stage pan-
creatic and liver cancer treatment.
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